Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration
Bristol Myers Squibb paid a $15 million milestone to partner Atrium Therapeutics following the successful delivery of a lead compound targeting an undisclosed cardiology indication. The payment falls under an existing global collaboration where Atrium remains eligible for up to $1.35 billion in R&D milestones and up to $825 million in commercial milestones.
Key figures
- Milestone payment
- 15000000
- Potential rd milestones
- $1.35 billion
- Potential commercial milestones
- $825 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.